6.23
+3.46(+124.91%)
Currency In NaN
| Previous Close | 2.77 |
| Open | 5.59 |
| Day High | 7.36 |
| Day Low | 5.14 |
| 52-Week High | 15.49 |
| 52-Week Low | 1.47 |
| Volume | 92.13M |
| Average Volume | 408,303 |
| Market Cap | 158.03M |
| PE | -1.05 |
| EPS | -6.15 |
| Moving Average 50 Days | 2.84 |
| Moving Average 200 Days | 3.4 |
| Change | 3.7 |
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update
GlobeNewswire Inc.
Yesterday at 8:05 PM GMT
Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate in the deep B-cell depleting category to receive
Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025
GlobeNewswire Inc.
Aug 25, 2025 8:05 PM GMT
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune dis
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 28, 2025 8:05 PM GMT
SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune dise